AbbVie's (ABBV) Q2 financial results are expected to be in line with expectations, RBC Capital Markets analysts said in a Friday note.
The company is scheduled to report its Q2 financial results on July 31.
Analysts said sentiment on AbbVie has changed significantly, especially after the recent Apogee deal, which addresses a primary overhang for the stock.
RBC lowered its adjusted earnings per share estimate for the company to $3.57 from $3.76. Analysts polled by FactSet expect $3.70.
RBC maintained an outperform rating on the stock and increased its price target to $280 from $260.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments